Table 2.

Summary of the MOF type, surface area, pore size, agents delivered, and cells/animals tested for drug delivery discussed in this review

MOF	BET surface area (m2 g−1)	Pore size (Å)	Agents delivered	Cells/animals tested	Refs
ZIF-8	1300	12	DOX	MCF-7 cells	[34]
			DOX	MDA-MB-468 cells	[103]
			DOX	B16F10 bearing mice	[106]
			Camptothecin	MCF-7 cells	[40]
			3-MA	HeLa cells	[55]
			Ceftazidime	Escherichia coli	[83]
			pEGFP-C1	MCF-7 cells	[127]
			VEGF aptamer/insulin/GOx	MCF-10A cells	[149]
			DOX/BSA	MCF-7 cells	[152]
MIL-100	1800	25 and 29	ICG	MCF-7 cells	[42]
			D-AzAla	MRSA-bearing mice	[81]
			Brimonidine tartrate	661 W cells	[84]
			DOX	HepG-2 cells	[36]
			Topotecan	PANC1 cells	[39]
MIL-101	2200	29 and 34	Cisplatin	HT-29 cells	[112]
			DOX	H22 tumor-bearing mice	[113]
			siRNAs	MCF-7/T cells	[130]
NU-1000	2200	12 and 30	Insulin	N.A	[82]
			Insulin/DNA	SK-OV cells	[151]
UiO-66	1200	8 and 12	Tamra-labeled DNA	HeLa cells	[68]
			AS1411/DOX	MCF-7 cells	[147]
UiO-67	2300	12 and 16	Brimonidine tartrate	661 W cells	[84]
UiO-68	4000	16 and 20	Cisplatin/siRNAs	SKOV-3 cells	[129]
			ATP/AS1411	MDA-MB-231	[148]
PCN-333	4000	42 and 55	Tyrosinase	RPMI-1640	[158]
ZIF-90	1300	11	Cas9	HeLa cells	[153]